Today: 21 May 2026
Microchip Technology stock jumps 10% after MCHP boosts Q3 sales outlook

Microchip Technology stock jumps 10% after MCHP boosts Q3 sales outlook

New York, January 6, 2026, 12:40 EST — Regular session

Microchip Technology Incorporated (MCHP) shares rose 10.2% to $73.93 in midday trading on Tuesday after the chipmaker lifted its fiscal third-quarter net sales outlook in a late-Monday update. The company now expects net sales of about $1.185 billion for the quarter ended Dec. 31, 2025, above its earlier $1.109 billion to $1.149 billion forecast, and said it would not hold a conference call on the update, with full results due Feb. 5. CEO Steve Sanghi said “our bookings activity was very strong in the December quarter,” referring to new orders, and the company pointed to a stronger March-quarter opening backlog, or unfilled orders, as it ramps factories to cut under-utilization charges, a cost of running plants below capacity. Microchip Technology Incorporated

The update is a fresh data point for investors tracking a chip “inventory correction,” a period when buyers run down excess stock and delay new orders. Microchip’s forecast lift sent the stock up 5.6% in after-hours trading on Monday, after the company pointed to improving demand as customers worked through chip stockpiles built during the pandemic. Reuters

Microchip is a broadline supplier of semiconductors to industrial and automotive customers, where demand can swing quickly with factory output and vehicle builds. Traders often watch bookings and backlog for early signs of a turn, since stronger order flow can lift factory use and improve margins as fixed costs get spread over more units.

An 8-K, a current report filed with U.S. regulators, was submitted on Jan. 5 and lists the business update under Item 2.02, the section used for operating results and financial condition.

Several brokers lifted targets on Tuesday. Needham analyst N. Quinn Bolton maintained a buy rating and raised his price target to $77 from $75, while Stifel’s Tore Svanberg lifted his target to $80 from $75, according to data compiled by Benzinga.

Still, the rally leaves less room for a stumble in end demand. If customers pause orders again or push out deliveries, Microchip could face renewed under-utilization costs and fresh charges tied to excess inventory.

Stock Market Today

  • Australia Shares Set to Rise at Open, New Zealand Markets Dip
    May 20, 2026, 7:49 PM EDT. Australian shares are expected to open higher, signaling investor confidence in the region's market outlook. In contrast, New Zealand equities are projected to decline at the open, reflecting differing economic or market responses. Market data sourced from ICE Data Services with reference information provided by FactSet, supported by multiple financial data providers. The divergence underscores the varied regional market trends in Oceania at the start of the trading session.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Fermi Inc (FRMI) stock jumps nearly 10% as class-action filing adds pressure
Previous Story

Fermi Inc (FRMI) stock jumps nearly 10% as class-action filing adds pressure

Boeing stock rises as Bernstein lifts target to $277, but 737 supply signals stay in focus
Next Story

Boeing stock rises as Bernstein lifts target to $277, but 737 supply signals stay in focus

Go toTop